Dakota Wealth Management Has $19.75 Million Stock Position in Medtronic PLC $MDT

Dakota Wealth Management boosted its holdings in Medtronic PLC (NYSE:MDT) by 31.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 205,541 shares of the medical technology company’s stock after buying an additional 48,826 shares during the period. Dakota Wealth Management’s holdings in Medtronic were worth $19,751,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Baker Tilly Wealth Management LLC grew its stake in shares of Medtronic by 3.3% in the fourth quarter. Baker Tilly Wealth Management LLC now owns 3,221 shares of the medical technology company’s stock worth $309,000 after acquiring an additional 102 shares during the last quarter. Riverbend Wealth Management LLC raised its stake in Medtronic by 3.2% during the 3rd quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after purchasing an additional 107 shares during the last quarter. Holistic Financial Partners boosted its holdings in Medtronic by 3.0% in the 3rd quarter. Holistic Financial Partners now owns 3,697 shares of the medical technology company’s stock valued at $352,000 after purchasing an additional 109 shares during the period. Wynn Capital LLC boosted its holdings in Medtronic by 2.4% in the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after purchasing an additional 110 shares during the period. Finally, Meridian Investment Counsel Inc. grew its position in Medtronic by 0.4% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock worth $2,692,000 after purchasing an additional 110 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MDT has been the subject of a number of research analyst reports. Daiwa Securities Group cut their price objective on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. CICC Research assumed coverage on Medtronic in a report on Friday, January 30th. They issued an “outperform” rating for the company. Barclays reiterated an “overweight” rating and issued a $118.00 price objective on shares of Medtronic in a research report on Wednesday, February 18th. Finally, Wells Fargo & Company began coverage on Medtronic in a report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $110.74.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Needham reaffirmed a Buy on MDT with a $120 price target, highlighting confidence in Medtronic’s multi‑year growth story and tuck‑in acquisition strategy, which supports upside expectations. Needham Reiterates Buy
• Positive Sentiment: FDA expanded the indication for the OmniaSecure defibrillation lead to allow placement in the left bundle branch area, broadening use for conduction‑system pacing and potentially increasing adoption in cardiac device procedures. OmniaSecure FDA Approval
• Positive Sentiment: Medtronic expanded its pain portfolio via a distribution agreement with Merit Medical to offer the FDA‑cleared ViaVerte basivertebral nerve ablation system — a minimally invasive, implant‑free option for chronic low‑back pain that can drive incremental sales in pain management. ViaVerte Distribution Deal
• Positive Sentiment: Market commentary reiterates the planned spin‑off of Medtronic’s high‑growth diabetes unit later this year — a strategic move investors view as value‑unlocking by creating a pure‑play diabetes company and a leaner core medtech business. Spin-Off Thesis
• Neutral Sentiment: Analyst coverage and articles (Zacks, TipRanks, others) largely frame recent news as mixed but keep consensus sentiment constructive — analysts expect multi‑year EPS growth despite the recent charge. Analyst Commentary
• Negative Sentiment: Medtronic cut FY‑2026 guidance after taking a charge tied to MiniMed approval and private equity considerations; this near‑term hit to earnings outlook is the primary reason shares are down as investors reassess short‑term profitability. Guidance Cut / MiniMed Charge

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $97.71, for a total value of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.26% of the stock is owned by company insiders.

Medtronic Stock Performance

NYSE MDT opened at $87.72 on Friday. The stock has a market cap of $112.62 billion, a P/E ratio of 24.43, a PEG ratio of 2.26 and a beta of 0.71. The company’s 50-day simple moving average is $95.99 and its 200 day simple moving average is $96.52. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter last year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).